UGT2B15 single nucleotide polymorphism reduces dabigatran acylglucuronide formation in humans
BackgroundDabigatran etexilate (DABE), a prodrug of dabigatran (DAB), is a direct thrombin inhibitor used to prevent ischemic stroke and thromboembolism during atrial fibrillation. The effect of genetic polymorphisms on its metabolism, particularly UGT2B15, has not been extensively explored in human...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Frontiers Media S.A.
2025-01-01
|
| Schriftenreihe: | Frontiers in Pharmacology |
| Schlagworte: | |
| Online-Zugang: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1507915/full |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|